Editas Medicine to Participate in Upcoming Investor Conference
On October 1, 2020, Editas Medicine (Nasdaq: EDIT) announced its participation in the Chardan Virtual 4th Annual Genetic Medicines Conference, scheduled for October 5, 2020, at 10:30 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On October 1, 2020, Editas Medicine (Nasdaq: EDIT) announced its participation in the Chardan Virtual 4th Annual Genetic Medicines Conference, scheduled for October 5, 2020, at 10:30 a.m. ET. The event will feature a fireside chat and will be webcast live on the company's website, with archived recordings available for 30 days post-event. Editas Medicine focuses on developing transformative genomic medicines using CRISPR technology to treat serious diseases. For more updates, visit www.editasmedicine.com.
Details
News Market Reaction – EDIT
The recorded move for EDIT in the trading session of this news was +0.39%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conference:
Chardan Virtual 4th Annual Genetic Medicines Conference
Fireside Chat
Date: Monday, October 5, 2020
Time: 10:30 a.m. ET
The event will be webcast live and may be accessed on the Editas Medicine website in the Investors and Media section. Archived recordings will be available for approximately 30 days following the event.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Investor Contact
Mark Mullikin
(617) 401-9083
mark.mullikin@editasmed.com
Media Contact
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.